特邀讲者
杨璐菡
杭州启函生物科技有限公司
更新时间：2020-09-30 15:22
Dr. Luhan Yang is Chief Executive Officer of Qihanbio, a company revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Dr. Yang leads a world class genome engineering team harnessing the latest gene-editing techniques with the capability to solve the global organ crisis by reinvigorating the field of xenotransplantation and offering the potential to expand the applicability of transplantation into other areas such as cell therapy. She previously developed the highly programmable genome-engineering tool, CRISPR/Cas9, for use in mammalian cells, and pioneered the first isogenic human stem cell lines to model human diseases at the tissue level. She was recently honored in the Bloomberg 50 (2017), named “Young Global Leader” by the World Economic Forum (2017) and was featured in “30 Under 30” in Science and Healthcare by Forbes Magazine (2014).
美迪康会务通